As of 2026-01-19, the Relative Valuation of Oramed Pharmaceuticals Inc (ORMP) is 19.69 USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.68 USD, the upside of Oramed Pharmaceuticals Inc based on Relative Valuation is 435.2%.
The range of the Relative Valuation is 16.04 - 22.01 USD.
| Range | Selected | |
| Trailing P/E multiples | 14.6x - 19.4x | 16.7x |
| Forward P/E multiples | 17.5x - 20.0x | 19.0x |
| Fair Price | 16.04 - 22.01 | 19.69 |
| Upside | 335.9% - 498.2% | 435.2% |
| Date | P/E |
| 2026-01-16 | 3.34 |
| 2026-01-15 | 3.35 |
| 2026-01-14 | 3.30 |
| 2026-01-13 | 3.08 |
| 2026-01-12 | 3.11 |
| 2026-01-09 | 3.11 |
| 2026-01-08 | 3.16 |
| 2026-01-07 | 2.97 |
| 2026-01-06 | 2.79 |
| 2026-01-05 | 2.69 |
| 2026-01-02 | 2.64 |
| 2025-12-31 | 2.59 |
| 2025-12-30 | 2.55 |
| 2025-12-29 | 2.64 |
| 2025-12-26 | 2.68 |
| 2025-12-24 | 2.86 |
| 2025-12-23 | 2.68 |
| 2025-12-22 | 2.69 |
| 2025-12-19 | 2.66 |
| 2025-12-18 | 2.70 |
| 2025-12-17 | 2.75 |
| 2025-12-16 | 2.80 |
| 2025-12-15 | 2.80 |
| 2025-12-12 | 2.79 |
| 2025-12-11 | 2.75 |
| 2025-12-10 | 2.63 |
| 2025-12-09 | 2.43 |
| 2025-12-08 | 2.44 |
| 2025-12-05 | 2.44 |
| 2025-12-04 | 2.47 |
| 2025-12-03 | 2.47 |
| 2025-12-02 | 2.50 |
| 2025-12-01 | 2.50 |
| 2025-11-28 | 2.59 |
| 2025-11-26 | 2.59 |
| 2025-11-25 | 2.61 |
| 2025-11-24 | 2.35 |
| 2025-11-21 | 2.34 |
| 2025-11-20 | 2.20 |
| 2025-11-19 | 2.26 |
| 2025-11-18 | 2.26 |
| 2025-11-17 | 2.12 |
| 2025-11-14 | 2.11 |
| 2025-11-13 | 2.18 |
| 2025-11-12 | 2.24 |
| 2025-11-11 | 2.20 |
| 2025-11-10 | 2.07 |
| 2025-11-07 | 1.99 |
| 2025-11-06 | 2.00 |
| 2025-11-05 | 2.03 |